132206-92-9

Basic information

• Synonyms: 4-Chloro-1H-imidazo[4,5-c]quinoline;4-chloro-3H-Imidazo[4,5-c]quinoline
• CAS NO: 132206-92-9
• Molecular Formula: C₁₀H₆ClN₃
• Molecular Weight: 203.62774
• Mol File: 132206-92-9.mol

Chemical Properties

• Melting Point: 257-258 °C
• Boiling Point: 508.4±30.0 °C(Predicted)
• Appearance: /
• Density: 1.515±0.06 g/cm3(Predicted)
• PKA: 7.72±0.40(Predicted)
• CAS DataBase Reference: N/A(CAS DataBase Reference)
• NIST Chemistry Reference: N/A(132206-92-9)
• EPA Substance Registry System: N/A(132206-92-9)

Safety Data

• Hazardous Substances Data: 132206-92-9(Hazardous Substances Data)

Upstream product

• 233-56-7 1H-imidazo[4,5-c]quinoline 
• 2099-63-0 anthranilic acid hydrochloride 
• 121845-92-9 2-<2-nitroethylideneamino>benzoic acid 
• 39061-97-7 4-chloro-3-nitroquinoline 
• 50332-66-6 3-nitro-quinolin-4-ol 
• 42606-33-7 3-nitro-4-aminoquinoline 
• 87751-33-5 quinoline-3,4-diamine 
• 132206-91-8 1H-imidazo<4,5-c>quinolin-5-oxide 

Downstream Products

• 132207-04-6 1H-imidazo[4,5-c]-quinolin-4-amine 
• 99011-02-6 imiqimod 
• 132207-05-7 N-phenyl-1H-imidazo<4,5-c>quinolin-4-amine 

Relevant articles and documents

A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS

The present invention relates to allosteric modulation of A3 adenosine receptor (A3AR) and provides for the use of an A3 adenosine receptor modulator (A3RM),for the preparation of pharmaceutical compositions for

Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor

1H-Imidazo[4,5-c]quinolin-4-amine derivatives have been synthesized as allosteric modulators of the human A3 adenosine receptor (AR). Structural modifications were made at the 4-amino and 2 positions. The compounds were tested in both binding and functional assays, and many were found to be allosteric enhancers of the action of A3AR agonists by several different criteria. First, a potentiation of the maximum efficacy of the agonist C1-IB-MECA was observed for numerous derivatives. Also, a number of these compounds decreased the rate of dissociation of the agonist [ 125I]I-AB-MECA from the A3AR. Most prominently, compound 43 (LUF6000) was found to enhance agonist efficacy in a functional assay by 45% and decrease dissociation rate similarly without influencing agonist potency. The structural requirements for allosteric enhancement at the A3AR were distinct from the requirements to inhibit equilibrium binding. Thus, we have prepared allosteric enhancers of the human A3AR that have an improved allosteric effect in comparison to the inhibition of equilibrium binding at the orthosteric site.

1H-imidazo?4,5-c!quinolin-4-amines

Novel 1H-imidazo?4,5-c!quinolin-4-amines are disclosed. The compounds function as antiviral agents and they are potential synthetic intermediates in the preparation of known antiviral agents and labeled known antiviral agents. Processes for the preparation of the compounds, methods for their antiviral use, and methods of inducing interferon biosynthesis, are also described.

1H-Imidazoquinolin-4-amines: Novel Non-Xanthine Adenosine Antagonists

On the basis of a model we recently developed for the antagonist binding site of the adenosine A1 receptor (J.Med.Chem. 1990, 33, 1708-1713), it was predicted that 1H-imidazoquinolin-4-amines would be antagonists of the A1 rec

Olefinic 1H-imidazo[4,5-c]quinolin-4-amines

Novel 1-substituted 1H-imidazo-[4,5-c]quinolin-4-amines are disclosed. These compounds function as antiviral agents, and they are potential synthetic intermediates in the preparation of known antiviral agents and labeled known antiviral agents. This inven